Latest Morpholines Stories
HILDEN, Germany and LONDON, July 28, 2014 /PRNewswire/ -- - Collaboration aims to create and commercialize companion diagnostic using genomic data
The Rottenstein Law Group, a national personal injury law firm, has launched a new website dedicated to providing the public information about the dangers of Xarelto and legal options if they
However, Access Barriers Result in Greater Prescribing of Conventional Anticoagulants, According to Findings from Decision Resources Group BURLINGTON, Mass., July 23, 2014 /PRNewswire/ -- Decision
Zoll, Kranz & Borgess, LLC, (ZKB), an experienced pharmaceutical and medical device litigation firm, is currently investigating claims of individuals who developed bleeding, clotting or other
Several Xarelto users are considering filing a Xarelto lawsuit after suffering dangerous side effects associated with the popular blood thinner drug Xarelto (rivaroxaban).
Additional Novel Oral Anticoagulants are Expected to Gain Approval in China for AF and VTE in the Next Three to Four Years, According to Findings from Decision Resources Group BURLINGTON, Mass.,
SAN DIEGO, May 28, 2014 /PRNewswire/ -- Ambit Biosciences (NASDAQ:AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune
Reliable Biopharmaceutical Corporation (RBC) announces the launch of cGMP MES Buffer.
The DrugNews Center is the web’s largest source for prescription drug warnings, research and legal news.
Quizartinib QUANTUM-R Phase 3 Trial Begins SAN DIEGO, May 6, 2014 /PRNewswire/ -- Ambit Biosciences (NASDAQ: AMBI), a biopharmaceutical company focused on discovery and development